Introducing Survodutide: Groundbreaking New Weight Loss Medication

In the past year alone, there has been a rapidly growing interest in weight loss medicines with certain manufacturers like Novo Nordisk and Eli Lilly meeting this demand with Wegovy and Mounjaro to dominate the weight loss market.

On the horizon, there appears to be a brand new weight loss medicine that claims to overtake that of the already-established giants. Survodutide is on its way to UK medical markets.

What is Survodutide?

Survodutide is a new weight loss medicine created by Zealand and Boehringer Ingelheim, designed to have a unique mechanism of action that will follow and even surpass other high-profile drugs currently in the market (i.e. Wegovy, Mounjaro and Ozempic). It is currently in its testing phases and has no anticipated release date.

What is the difference between Survodutide and other weight loss injections?

Unlike other weight loss medicines, Survodutide is a dual agonist focussed specifically on glucagon receptors. Glucagon is responsible for regulating blood sugars, meaning that it is also good for patients suffering from Type 2 Diabetes. Additionally, it not only targets weight loss and diabetes-related issues, but it is also able to aid with liver disease, specifically nonalcoholic steatohepatitis. 

With its multipurpose use targeting more than just blood sugar, Survodutide is due to make big changes in the medical weight loss world.

When will Survodutide be available? What are some alternative weight loss treatments that I can use?

As Survodutide is still in its testing phases, there is no sign of it being available at the moment. In the meantime, there are other weight loss medicines in the market that still show effective results. You can find Mounjaro, Wegovy – and if you are using it for Type 2 Diabetes – Ozempic available to buy online at us.